Commodore Capital LP and Affiliates File Schedule 13G for Terns Pharmaceuticals, Inc.

Commodore Capital LP, along with its affiliates Commodore Capital Master LP, Michael Kramarz, and Robert Egen Atkinson, have filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 4,650,000 shares of Common Stock in Terns Pharmaceuticals, Inc. This represents approximately 5.3% of the total outstanding shares. The filing indicates that Commodore Capital LP, as the investment manager to Commodore Capital Master LP, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson, as managing partners of Commodore Capital LP, exercise investment discretion over these securities. The filing is made pursuant to Rule 13d-1(c) and includes a joint filing agreement among the parties.